文献速递淋巴瘤

BNT162b2 mRNA COVID-19疫苗在B细胞非霍奇金淋巴瘤患者中的疗效

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

该研究评估了BNT162b2 mRNA COVID-19疫苗在149例B细胞非霍奇金淋巴瘤(B-NHL)患者中的体液免疫应答,并与65例健康对照比较。结果显示,B-NHL患者血清阳性应答率为49%,显著低于健康对照的98.5%(P < .001);正在接受利妥昔单抗/奥妥珠单抗(R/Obi)治疗者应答率仅7.3%。暴露于R/Obi后时间较长和绝对淋巴细胞计数≥0.9 × 10^3/μL可预测阳性血清学应答。

要点

  • B-NHL患者接种BNT162b2后血清阳性率49%,显著低于健康对照98.5%。
  • 正在接受R/Obi治疗者应答率仅7.3%,治疗初治者89%,末次R/Obi治疗>6个月者66.7%。
  • 较长R/Obi暴露间隔和绝对淋巴细胞计数≥0.9 × 10^3/μL预测阳性应答。

核心结论

  • 正在接受R/Obi治疗的B-NHL患者对BNT162b2 mRNA COVID-19疫苗的体液应答受损。
  • 暴露于R/Obi后时间越长,疫苗应答率越高。

研究设计与样本

  • 研究纳入149例B-NHL患者(侵袭性47%,惰性53%)和65例健康对照,均接种2剂BNT162b2,间隔21天。
  • 第二剂后2至3周采用Elecsys Anti-SARS-CoV-2S检测抗体滴度。

主要发现

  • B-NHL患者血清阳性应答率为49%,健康对照为98.5%(P < .001)。
  • 未治疗、正在R/Obi治疗、末次R/Obi>6个月患者的血清阳性率分别为89%、7.3%、66.7%。
  • 多因素分析显示较长R/Obi暴露间隔和绝对淋巴细胞计数≥0.9 × 10^3/μL预测阳性血清学应答。
  • 抗CD20抗体治疗患者中,惰性B-NHL达到阳性血清学的中位时间长于侵袭性B-NHL。

临床怎么用

  • 对正在接受R/Obi治疗的B-NHL患者,应预期BNT162b2疫苗体液应答率低。
  • 可考虑根据R/Obi暴露间隔和绝对淋巴细胞计数评估疫苗应答可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients diagnosed with B-cell non-Hodgkin lymphoma (B-NHL), particularly if recently treated with anti-CD20 antibodies, are at risk of severe COVID-19 disease. Because studies evaluating humoral response to COVID-19 vaccine in these patients are lacking, recommendations regarding vaccination strategy remain unclear. The humoral immune response to BNT162b2 messenger RNA (mRNA) COVID-19 vaccine was evaluated in patients with B-NHL who received 2 vaccine doses 21 days apart and compared with the response in healthy controls. Antibody titer, measured by the Elecsys Anti-SARS-CoV-2S assay, was evaluated 2 to 3 weeks after the second vaccine dose. Patients with B-NHL (n = 149), aggressive B-NHL (a-B-NHL; 47%), or indolent B-NHL (i-B-NHL; 53%) were evaluated. Twenty-eight (19%) were treatment naïve, 37% were actively treated with a rituximab/obinutuzumab (R/Obi)-based induction regimen or R/Obi maintenance, and 44% had last been treated with R/Obi >6 months before vaccination. A seropositive response was achieved in 89%, 7.3%, and 66.7%, respectively, with response rates of 49% in patients with B-NHL vs 98.5% in 65 healthy controls (P < .001). Multivariate analysis revealed that longer time since exposure to R/Obi and absolute lymphocyte count ≥0.9 × 103/μL predicted a positive serological response. Median time to achieve positive serology among anti-CD20 antibody-treated patients was longer in i-B-NHL vs a-B-NHL. The humoral response to BNT162b2 mRNA COVID-19 vaccine is impaired in patients with B-NHL who are undergoing R/Obi treatment. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. This study is registered at www.clinicaltrials.gov as #NCT04746092.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021. PMID: 34387648. doi:10.1182/bloodadvances.2021005094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。